ÍøºìºÚÁÏ

Skip to main content
(352) 273-8740

Ali Ataya, MD : Research

Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)

Photo of Ali Ataya
(352) 273-8740 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • Dyspnea , 10 publications
  • Pulmonary Alveolar Proteinosis , 4 publications
  • Lymphangioleiomyomatosis , 4 publications
  • Fever , 4 publications

Research activity

122 publications

396 citations

Why is this important?

Active clinical trials

Prosera

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - 75 Years
Sexes
All
Hemotag
Investigator
Ali Ataya
Status
Accepting Candidates
ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

122 publications

2025

A patient journey map for people living with autoimmune pulmonary alveolar proteinosis

Respiratory Medicine

2025

Case report: Novel homozygous ACVRL1 missense variant in a family with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension: findings suggest a hypomorphic allele.

Frontiers in genetics

•

2025

Concurrent limited cutaneous systemic sclerosis and hereditary haemorrhagic telangiectasia.

The Lancet. Haematology

•

2025

Development of New Intrapulmonary Shunts in Pulmonary Arterial Hypertension Patients Treated with Sotatercept

American Journal of Respiratory and Critical Care Medicine

2025

Glycogen storage disease type V: delayed diagnosis of a cause of exercise intolerance in a patient with hereditary haemorrhagic telangiectasia.

BMJ case reports

•